3 May 2016: Aesica Pharmaceuticals, the global pharmaceutical contract development and manufacturing organisation (CDMO), is one of the leading authorities within its industry to strategically embrace growing market demand for complete one-stop-shop service provision from providers with the foresight to heavily consolidate their supply chain. Such CDMOs are driving up the value of their services to customers – with operational strategies in place that enable the optimal performance and efficient delivery of everything from API manufacture, formulation development through to clinical batch and commercial scale manufacturing.
Forward looking, end-to-end CDMO service providers, like Aesica Pharmaceuticals, are adding exceptional value to the supply chain. They have the distinct advantage of full visibility over the product’s entire life cycle and consequently are able to control and run the entire supply chain much more effectively than if carried out by multiple CDMOs. High quality, on-time-in-full (OTIF) service delivery is optimised with maximum scope for continuous improvement. This has the ultimate effect of faster time to market.
Such complete service provision brings a massive benefit to the market by making it easy to identify and then remove redundant and unnecessary activities – thereby streamlining and maximizing supply chain efficiency. Significant time and resources are saved for customers who are freed from the burden of engaging multiple partners.
Moreover, such CDMOs are in a position to ensure that there is no loss of time due to tech transfers – with the seamless transition from development through to clinical batch and then on through to commercial scale manufacturing.
Ian Muir, Managing Director at Aesica Pharmaceuticals commented: “I am highly confident that CDMOs, offering the clear advantages of supply chain consolidation by providing such a complete set of services from a single entity, will continue to innovate with solutions that make a real added value difference to the supply chain. Indeed, in the case of Aesica, the creation of our new Development Centre at Queenborough, combined with our full commercial capabilities on the same site, is a case in point.” He continued: “Ultimately, continuous and optimized improvement in efficiencies eliminates wasted resource whilst most crucially reducing inventory and working capital and speeding our customers products to market to the benefit of patients.”